Did you know that your version of Internet Explorer is out of date?
To get the best possible experience using our website we recommend downloading one of the below web browsers.

Internet Explorer 9, Firefox, Chrome, or Safari.

Treatment Access News

INESSS now in year 2 of firbrosis requirements scale-back

march 28, 2016

The Institut national d’excellence en santé et en services sociaux (INESSS) in Quebec is now in its second year of implementing a scale-back of fibrosis requirements for people living with chronic hepatitis C. This means that the reimbursement criteria in Quebec is now a fribrosis score of F1 if there are poor prognosis factors, F2/F3 otherwise. Previously the requirements were F3/F4 without consideration for poor prognosis factors. 

INESSS identifies “poor prognosis factors” as the below:

  • · organ transplantation (pre- or post-transplantation);
    · severe extra-hepatic manifestations of hepatitis C (e.g. type II or III mixed cryoglobulinemia with damage to the organs, vasculitis, nephropathy, B-cell non-Hodgkin's lymphoma);
    · HIV or HBV co-infection;
    · other liver disease (e.g. nonalcoholic steatohepatitis);
    · type-2 diabetes;
    · porphyria cutanea tarda.

HIV/HCV co-infection is a poor prognosis factor that may hasten access to HCV meds. 

Read the expanded reimbursement criteria here.